US 11,806,364 B2
Method for producing myeloid-derived suppressor cells, myeloid-derived suppressor cells produced thereby, and methods thereof
Sung Jae Shin, Seoul (KR); Woo Sik Kim, Seoul (KR); Hong Min Kim, Seoul (KR); Kee Woong Kwon, Seoul (KR); Joo Heon Yoon, Seoul (KR); and Won Jung Koh, Seoul (KR)
Assigned to Industry-Academic Cooperation Foundation, Yonsei University, Seoul (KR); and Research & Business Foundation Sungkyunkwan University, Gyeonggi-do (KR)
Appl. No. 16/652,349
Filed by Industry-Academic Cooperation Foundation, Yonsei University, Seoul (KR); and Research & Business Foundation Sungkyunkwan University, Gyeonggi-do (KR)
PCT Filed Sep. 28, 2018, PCT No. PCT/KR2018/011558
§ 371(c)(1), (2) Date Mar. 30, 2020,
PCT Pub. No. WO2019/066571, PCT Pub. Date Apr. 4, 2019.
Claims priority of application No. 10-2017-0125968 (KR), filed on Sep. 28, 2017; application No. 10-2017-0125990 (KR), filed on Sep. 28, 2017; and application No. 10-2017-0126379 (KR), filed on Sep. 28, 2017.
Prior Publication US 2020/0316117 A1, Oct. 8, 2020
Int. Cl. A61K 35/15 (2015.01); C12N 5/077 (2010.01)
CPC A61K 35/15 (2013.01) [C12N 5/0669 (2013.01); C12N 2501/22 (2013.01); C12N 2501/2306 (2013.01); C12N 2501/24 (2013.01)] 15 Claims
 
1. A method for producing myeloid-derived suppressor cells (MDSCs), comprising: a step of treating bone marrow cells with a toll-like receptor agonist (TLR agonist) or type I interferon, to induce differentiation into myeloid-derived suppressor cells,
wherein the toll-like receptor agonist is at least one of toll-like receptor 7 agonist and toll-like receptor 9 agonist,
wherein the myeloid-derived suppressor cells comprise MDSCs having phenotype PDCA-1+, and
wherein the toll-like receptor agonist or the type I interferon is applied at the initiation time of bone marrow cell differentiation, and then is applied one or more times within 3 days after the initiation of differentiation.